What is the FIB-4 Index?
The Fibrosis-4 (FIB-4) index is a simple, non-invasive scoring tool used to estimate the amount of scarring (fibrosis) in the liver. It combines four routinely available values — patient age, two liver enzymes (AST and ALT), and platelet count — into a single number. Originally developed for patients with viral hepatitis, it is now widely applied to screen for advanced fibrosis in conditions such as non-alcoholic fatty liver disease (NAFLD/MASLD). This tool is for educational use and does not replace clinical judgement.
How to use this calculator
Enter the patient's age in years, the AST and ALT enzyme levels in U/L, and the platelet count in 109/L (the same as ×10³/µL). Press calculate to get the FIB-4 score along with its risk category. Make sure lab values come from the same blood draw for the most meaningful result.
The formula explained
$$\text{FIB-4} = \frac{\text{Age} \times \text{AST}}{\text{Platelets} \times \sqrt{\text{ALT}}}$$ Age and AST raise the score, while higher platelets and ALT lower it. The logic reflects that liver damage tends to raise AST relative to ALT and reduces platelet production, so a higher score signals more likely fibrosis.
Worked example
For a 55-year-old with AST = 40, ALT = 30 and platelets = 150: numerator = \(55 \times 40 = 2200\); denominator = \(150 \times \sqrt{30} = 150 \times 5.4772 = 821.58\); $$\text{FIB-4} = \frac{2200}{821.58} \approx 2.68$$ This falls in the indeterminate range (1.45–3.25), suggesting further evaluation may be warranted.
Interpreting Your FIB-4 Result
The FIB-4 index combines age, AST, ALT and platelet count into one number used to screen for advanced liver fibrosis (stage F3–F4). It is calculated as \(\text{FIB-4} = \frac{ \text{Age} \times \text{AST} }{ \text{Platelets} \times \sqrt{\text{ALT}} }\), with AST and ALT in U/L and platelets in 109/L. It is a triage tool, not a diagnosis.
The three zones
- Below 1.45 (low): advanced fibrosis is unlikely. In the original Sterling 2006 validation (patients with HIV/hepatitis C co-infection), a cut-off of 1.45 gave a negative predictive value of roughly 90% for advanced fibrosis.
- 1.45 to 3.25 (indeterminate): the score cannot reliably rule fibrosis in or out. A large share of people fall in this zone, and it usually leads to further testing such as transient elastography (FibroScan) or another biomarker panel.
- Above 3.25 (high): advanced fibrosis is likely. In the same Sterling study, this cut-off gave a positive predictive value of about 65%, with high specificity. The exact figure depends on the population and how common fibrosis is in it.
Predictive values depend heavily on how common advanced fibrosis is in the group tested. They are higher in specialist clinics than in primary care or the general population.
Age-adjusted cut-off
Because age is in the numerator, FIB-4 tends to run higher in older adults and can over-call risk. McPherson and colleagues (studies in non-alcoholic fatty liver disease) proposed a lower cut-off of about 2.0 for adults aged 65 and over, instead of 1.45, to improve specificity. Some NAFLD/MASLD guidance also uses 1.3 (not 1.45) as the lower cut-off and 2.67 as the upper one; see the reference table.
Limitations
- Less accurate under about age 35 and over about age 65.
- AST and ALT can be raised by acute hepatitis, drug-induced injury, strenuous exercise, or muscle injury, which distorts the score.
- Low platelets from causes other than liver disease (some blood disorders, medications) can inflate the result.
- It was validated mainly in viral hepatitis and fatty liver disease, and performs differently in other liver conditions.
This page is educational only. It is not a diagnosis or medical advice. Please discuss your results with a qualified healthcare professional.
FIB-4 Score Reference Table
| FIB-4 score range | Risk of advanced fibrosis (F3–F4) | Typical next step in published guidance |
|---|---|---|
| < 1.45 (or < 2.0 for age ≥ 65) | Low | Advanced fibrosis unlikely. Manage underlying risk factors (weight, alcohol, diabetes, viral hepatitis) and repeat the assessment periodically, often every 1–3 years depending on risk. |
| 1.45 – 3.25 | Indeterminate | Second-line test such as transient elastography (FibroScan) or a patented serum marker (e.g. ELF) to clarify risk. |
| > 3.25 | High | Likely advanced fibrosis. Referral to hepatology/specialist assessment, confirmatory elastography or imaging, and evaluation for complications of cirrhosis. |
Source of cut-offs: 1.45 and 3.25 come from Sterling et al., Hepatology 2006 (HIV/HCV co-infected patients). The age-adjusted lower cut-off of 2.0 for age 65 and over comes from McPherson et al. (NAFLD cohorts). The next steps summarize the general approach of AASLD and EASL non-invasive testing guidance.
Note: Recent AASLD (MASLD) and EASL guidance commonly use slightly different thresholds: below 1.3 for low risk and 2.67 or above for high risk. Which cut-offs apply depends on the condition being assessed and the guideline your clinician follows.
FIB-4 Score Across Example Scenarios
Each value comes from \(\text{FIB-4} = \frac{ \text{Age} \times \text{AST} }{ \text{Platelets} \times \sqrt{\text{ALT}} }\). AST and ALT are in U/L and platelets in 109/L. Zones use the 1.45 and 3.25 cut-offs, with 2.0 as the lower cut-off for age 65 and over.
| Scenario | Age | AST | ALT | Platelets | Calculation | FIB-4 | Zone |
|---|---|---|---|---|---|---|---|
| Young adult, normal labs | 35 | 25 | 30 | 250 | \(\frac{35 \times 25}{250 \times 5.477} = \frac{875}{1369.3}\) | 0.64 | Low |
| Middle-aged, mild changes | 55 | 40 | 30 | 150 | \(\frac{55 \times 40}{150 \times 5.477} = \frac{2200}{821.6}\) | 2.68 | Indeterminate |
| Low platelets raise the score | 45 | 30 | 30 | 100 | \(\frac{45 \times 30}{100 \times 5.477} = \frac{1350}{547.7}\) | 2.46 | Indeterminate |
| Older adult, elevated enzymes | 62 | 80 | 50 | 110 | \(\frac{62 \times 80}{110 \times 7.071} = \frac{4960}{777.8}\) | 6.38 | High |
| Age 65+, borderline | 70 | 35 | 35 | 200 | \(\frac{70 \times 35}{200 \times 5.916} = \frac{2450}{1183.2}\) | 2.07 | Indeterminate (above the age-adjusted 2.0 cut-off) |
The third row shows the effect of platelets. With the same age, AST and ALT but platelets of 250 instead of 100, the score would be \(\frac{1350}{250 \times 5.477} \approx 0.99\) (low). Falling platelets raise the score substantially, and platelets can drop for reasons unrelated to the liver. These examples are illustrative only and are not medical advice.
FAQ
What do the cut-offs mean? A score below 1.45 indicates low risk of advanced fibrosis; above 3.25 indicates high risk; between the two is indeterminate and may need additional testing such as elastography.
Which units should I use? AST and ALT in U/L, platelets in 109/L (×10³/µL), and age in years.
Is FIB-4 a diagnosis? No. It is a screening estimate. Only a clinician can diagnose liver fibrosis, often confirmed with imaging or biopsy.